Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<sup>68</sup>Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2021

Same author

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.

Neuro-oncology·2021

Same author

DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics.

The Journal of molecular diagnostics : JMD·2021

Same author

Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas.

Cancer discovery·2021

Same author

Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.

Acta neuropathologica·2021

Same author

Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2021

Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026

Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026

Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026

Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026

Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026

Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 15, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Mutation specific antibodies: tool or dinosaur?

Andreas von Deimling, Felix Sahm, David Capper

|September 26, 2012

Summary

This summary is machine-generated.

Mutation-specific antibodies enhance cancer diagnostics by integrating molecular data with traditional expertise. Screening for BRAFV600E mutations in colon carcinoma patients may benefit upcoming clinical trials targeting BRAF and EGFR inhibitors.

More Related Videos

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Related Experiment Videos

Last Updated: Dec 15, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Area of Science:

Oncology
Molecular Diagnostics
Translational Research

Background:

Mutation-specific antibodies offer a novel approach to integrate molecular findings with conventional diagnostic methods.
The sustainable benefit of this combined approach in clinical practice requires further evaluation.

Discussion:

Data presented at ESMO 2012 on colon carcinoma highlights the potential of this integrated strategy.
The study suggests screening for the BRAFV600E mutation is crucial for patient stratification.

Key Insights:

Merging molecular diagnostics with traditional expertise improves diagnostic accuracy.
BRAFV600E mutation screening is a key step for patient selection in targeted therapy trials.

Outlook:

Upcoming clinical trials will combine BRAF and EGFR inhibitors for patients with BRAFV600E-positive colon carcinoma.
This approach may lead to more personalized and effective colon cancer treatment strategies.